Structure Based Compact Model for Output Capacitance of Trench Field-Plate MOSFET to Enable Power Loss Prediction

We propose a structure based compact model for out-put capacitance (Coss) of trench Field-Plate MOSFET. Ap-propriate equations were considered for Coss curves in three regions. Output charge (Qoss) and stored energy (Eoss) that were calculated by the proposed model corre-sponded very well to TCAD results. In assumption of 10 A and 2 MHz operation, conduction loss of 1.0 W and out-put charge loss of 1.26 W were estimated.2017 International Conference on Solid State Devices and Materials (SSDM2017), Sendai International Center, Sendai, Japan, September 19-22, 201

Immunohistochemical Character of Hepatic Angiomyolipoma: For Its Management

Hepatic angiomyolipoma (AML) is notoriously difficult to diagnose without an invasive surgery even with the recent development of the various imaging modalities. Additionally, recent reports showed its malignant behavior after the surgery; it is important to diagnose the character of each tumor including the possible malignant potential and determine the postoperative management for each case. For this purpose, we have reviewed reports and focused on the immunohistochemical staining with p53 and ki67 of the tumors showing the representative case of 60-year-old female. The imaging study of her tumor showed the character similar to the hepatocellular carcinoma, and she underwent the hepatectomy. The resected tumor stained positive for HMB-45 that is a marker of the AML, and 30–50% of the tumor cells were positively stained with Ki67 that is a mitotic marker. Also, the atypical epithelioid cells displayed p53 immunoreactivity. These results suggest the malignant potential of our tumor based on the previous reports; therefore the careful followup for this case is necessary for a long period whether it shows metastasis, sizing up, and so forth

Structure-based capacitance modeling and power loss analysis for the latest high-performance slant field-plate trench MOSFET

Field-plate trench MOSFETs (FP-MOSFETs), with the features of ultralow on-resistance and very low gate–drain charge, are currently the mainstream of high-performance applications and their advancement is continuing as low-voltage silicon power devices. However, owing to their structure, their output capacitance (Coss), which leads to main power loss, remains to be a problem, especially in megahertz switching. In this study, we propose a structure-based capacitance model of FP-MOSFETs for calculating power loss easily under various conditions. Appropriate equations were modeled for Coss curves as three divided components. Output charge (Qoss) and stored energy (Eoss) that were calculated using the model corresponded well to technology computer-aided design (TCAD) simulation, and we validated the accuracy of the model quantitatively. In the power loss analysis of FP-MOSFETs, turn-off loss was sufficiently suppressed, however, mainly Qoss loss increased depending on switching frequency. This analysis reveals that Qoss may become a significant issue in next-generation high-efficiency FP-MOSFETs

Association of CYP2R1 Gene Polymorphisms with Asthma and COPD in Japanese Patients

CYP2R1 is an enzyme involved in vitamin D metabolism, and SNPs in the CYP2R1 gene are associated with asthma. We compared the SNPs rs10741657 and rs12794714 in CYP2R1 among 69 patients with chronic obstructive pulmonary disease (COPD), 77 patients with bronchial asthma (BA), and 50 healthy donors (HDs). The SNPs were identified in oral mucosal cells using specific thermal-elution chromatography. For both SNPs, the A allele frequency was higher in COPD than in BA patients and HDs. For both SNPs, the AA/AG genotype with COPD was associated with significantly lower peripheral eosinophil counts and higher peripheral neutrophil counts than the AA/AG genotypes with BA. In addition, the AA/AG genotype with COPD was associated with significantly lower FEV1 than the AA/AG genotype with BA. Moreover, for rs12794714, the GG genotype with COPD was associated with significantly lower FEV1 than the AA/AG and GG genotypes with BA p < 0.01 and 0.05, respectively. The AA/AG genotype of both SNPs with COPD appears associated with neutrophilic, rather than eosinophilic inflammation, and the GG genotype of rs12794714 with COPD seems associated with bronchial obstruction versus BA. CYP2R1 SNPs might relate to neutrophilic inflammation and bronchial obstruction in COPD in Japanese people.journal articl

Correlation between Serum Vitamin D Binding Protein and Serum Calcium in Bronchial Asthma and the Effects of Single Nucleotide Polymorphisms

Bronchial asthma (BA) is characterized by airway stenosis due to chronic airway inflammation. CYP2R1 is an enzyme primarily responsible for vitamin D metabolism, and some of its single nucleotide polymorphisms (SNPs) have been implicated in BA. Vitamin D binding protein (VDBP) is primarily responsible for vitamin D transport, and some of its SNPs have also been implicated in asthma. Here, we investigated the relationship between serum VDBP, serum 25(OH)D, and serum calcium, as well as correlations between serum VDBP and laboratory data, in Japanese patients with BA and healthy donors (HDs). We also compared results between genotypes at SNPs of CYP2R1 (rs12794714 and rs10741657) and an SNP of VDBP (rs7041). Serum VDBP levels were significantly higher in the BA group compared with the HD group. Laboratory data did not differ between SNP genotypes in either group. The only parameter significantly correlated with VDBP was serum calcium in both groups. In addition, serum VDBP was correlated with serum calcium in all genotypes in the HD group, but was correlated with only the AA/AG genotype at rs12794714 and rs10741657 and TT/TG genotype at rs7041 in the BA group. Thus, SNP genotypes with an A allele (AA and AG) at rs12794714 and rs10741657 and a T allele (TT and TG) at rs7041, but not the GG genotype, may be involved in the serum VDBP-mediated regulation of serum calcium in BA.journal articl

A Case of Liver Injury as an Immune-related Adverse Event in Squamous Cell Carcinoma of the Lung with Successful Life-saving Treatment

A patient with lung squamous cell carcinoma, cT4N3M1c (OSS), Stage IVB developed Grade 4 hepatic impairment after 2 cycles of carboplatin + paclitaxel + nivolumab + ipilimumab as first-line chemotherapy. Clinically, an immune-related adverse event (irAE) was suspected and pulse therapy with 1 g methylprednisolone for 3 days was administered twice, followed by prednisolone 100 mg/day and mycophenolate mofetil 2000 mg/day, resolving the hepatic impairment. Immune checkpoint inhibitors can cause severe irAEs, as in the present case where cytotoxic chemotherapy combined with anti-PD-1 and anti-CTLA-4 antibodies caused Grade 4 irAE liver injury, which was successfully treated with steroids and immunosuppressants.journal articl

Path Cover Problems with Length Cost

For a graph G= (V, E) , a collection P of vertex-disjoint (simple) paths is called a path cover of G if every vertex v∈ V is contained in exactly one path of P. The Path Cover problem (PC for short) is to find a minimum cardinality path cover of G. In this paper, we introduce generalizations of PC, where each path is associated with a weight (cost or profit). Our problem, Minimum (Maximum) Weighted Path Cover [MinPC (MaxPC)], is defined as follows: Let U= { 0 , 1 , ⋯ , n- 1 }. Given a graph G= (V, E) and a weight function f: U→ R∪ { + ∞, - ∞} that defines a weight for each path based on its length, the objective of MinPC (MaxPC) is to find a path cover P of G such that the total weight of the paths in P is minimized (maximized). Let L be a subset of U, and PL be the set of paths such that each path is of length ℓ∈ L. We consider MinPLPC with binary cost, i.e., the cost function is f(ℓ) = 1 if ℓ∈ L; otherwise, f(ℓ) = 0. We also consider MaxPLPC with f(ℓ) = ℓ+ 1 , if ℓ∈ L; otherwise, f(ℓ) = 0. Many well-known graph theoretic problems such as the Hamiltonian Path and the Maximum Matching problems can be modeled using MinPLPC and MaxPLPC. In this paper, we first show that deciding whether MinP{ 0 , 1 , 2 }PC has a 0-weight solution is NP-complete for planar bipartite graphs of maximum degree three, and consequently, (i) for any constant σ≥ 1 , there is no polynomial-time approximation algorithm with approximation ratio σ for MinP{ 0 , 1 , 2 }PC unless P = NP, and (ii) MaxP{3,⋯,n-1}PC is NP-hard for the same graph class. Next, we present a polynomial-time algorithm for MinP{,1,⋯,k}PC on graphs with bounded treewidth for a fixed k. Lastly, we present a 4-approximation algorithm for MaxP{3,⋯,n-1}PC, which becomes a 2.5-approximation algorithm for subcubic graphs.journal articl

Direct observation of quasi-particle band in CeIrIn5_5: Angle-resolved photoemission spectroscopy study

We have performed a high-resolution angle resolved Ce 4$d-4f$ resonant photoemission experiment on the heavy fermion superconductor CeIrIn$_5$. We have observed a quasi-particle band which has an energy dispersion of $\sim 30$ meV in the Ce 4$f$ on-resonance spectra. The result suggests that although the 4$f$ spectra are dominated by the localized/correlated character, the small itinerant component is responsible for the superconductivity in this compound.Comment: 5 pages, 3 figure

Path Cover Problems with Length Cost

For a graph G=(V,E), a collection P of vertex-disjoint (simple) paths is called a path cover of G if every vertex v∈V is contained in exactly one path of P. The PATH COVER problem (PC for short) is to find a minimum cardinality path cover of G. In this paper, we introduce generalizations of PC, where each path is associated with a weight (cost or profit). Our problem, MINIMUM (MAXIMUM) WEIGHTED PATH COVER (MinPC (MaxPC)), is defined as follows: Let U={0,1,…,n−1}. Given a graph G=(V,E) and a weight function f:U→R∪{+∞,−∞}, which defines a weight for each path in its length, MinPC (MaxPC) is to find a path cover P of G such that the total weight of the paths in P is minimized (maximized). Let L be a subset of U, and PL be the set of paths such that each path is of length ℓ∈L. We especially consider MinPLPC with 0–1 cost, i.e., the cost function is f(ℓ)=1 if ℓ∈L; otherwise f(ℓ)=0. We also consider MaxPLPC with f(ℓ)=ℓ+1, if ℓ∈L; otherwise f(ℓ)=0. That is, MaxPLPC is to maximize the number of vertices contained in the paths with length ℓ∈L in a path cover. In this paper, we first show that MinP{0,1,2}PC is NP-hard for planar bipartite graphs of maximum degree three. This implies that (i) for any constant σ≥1, there is no polynomial-time approximation algorithm with approximation ratio σ for MinP{0,1,2}PC unless P=NP, and (ii) MaxP{3,…,n−1}PC is NP-hard for the same graph class. Next, (iii) we present a polynomial-time algorithm for MinP{0,1,…,k}PC on graphs with bounded treewidth for a fixed k. Lastly, (iv) we present a 4-approximation algorithm for MaxP{3,…,n−1}PC, which becomes a 2.5-approximation for subcubic graphs.16th International Conference and Workshops, WALCOM 2022, March 24–26, 2022, Jember, Indonesiajournal articl

Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk. Patients and methods: Treatment-naive patients with mCC-RCC were randomized to receive open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was first-line progression-free survival (PFS). The secondary endpoints were total PFS and overall survival (OS). Results: Of the 124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated. The median first-line PFS duration was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.42-1.08). The total PFS and OS were not significantly different between the SU/SO and SO/SU groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-1.246; and 38.4 and 30.9 months; HR, 0.934; 95% CI, 0.588-1.485, respectively). The subgroup analysis revealed that the total PFS with SU/SO was superior to the total PFS with SO/SU in the patients with favorable MSKCC risk and those with Conclusions: No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms (ClinicalTrials.gov identifier, NCT01481870)